{"id":"cladribine-tablets","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cladribine is a deoxyadenosine analog that is phosphorylated intracellularly and incorporated into DNA, leading to strand breaks and apoptosis. It preferentially affects lymphocytes due to their high deoxycytidine kinase activity and low 5'-nucleotidase activity, making it useful in hematologic malignancies and autoimmune conditions.","oneSentence":"Cladribine is a purine nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing selective depletion of lymphocytes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:18:35.920Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hairy cell leukemia"},{"name":"Multiple sclerosis (relapsing forms)"}]},"trialDetails":[{"nctId":"NCT05797740","phase":"","title":"Cladribine Tablets Level of Response Predictors in Clinical Practice (CLODINA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2023-08-03","conditions":"Multiple Sclerosis","enrollment":367},{"nctId":"NCT06415864","phase":"","title":"Oral Cladribine B-cell Study","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2019-07-01","conditions":"Multiple Sclerosis","enrollment":10},{"nctId":"NCT03933202","phase":"","title":"A Study of Suboptimally Controlled Participants Previously Taking Oral or Infusion DMDs for RMS (MASTER-2)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-07-22","conditions":"Multiple Sclerosis","enrollment":291},{"nctId":"NCT04178005","phase":"PHASE4","title":"Cladribine Tablets After Treatment With Natalizumab (CLADRINA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2020-02-19","conditions":"Multiple Sclerosis","enrollment":40},{"nctId":"NCT03500328","phase":"NA","title":"Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Johns Hopkins University","startDate":"2018-05-02","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":900},{"nctId":"NCT04695080","phase":"PHASE2, PHASE3","title":"ChariotMS - Cladribine to Halt Deterioration in People With Advanced Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2021-06-25","conditions":"Advanced Multiple Sclerosis, Progressive Multiple Sclerosis","enrollment":204},{"nctId":"NCT04934800","phase":"","title":"Prospective Effectiveness and Safety Study of Cladribine in Participants Who Change First-line DMD Treatments for Multiple Sclerosis (CLAD CROSS)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2019-12-10","conditions":"Multiple Sclerosis","enrollment":256},{"nctId":"NCT03963375","phase":"PHASE4","title":"Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2019-10-28","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":47},{"nctId":"NCT06887426","phase":"","title":"Cladribine Tablets as an Exit Therapy Strategy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2025-06","conditions":"Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":450},{"nctId":"NCT03933215","phase":"","title":"A Study of Suboptimally Controlled Participants Previously Taking Injectable DMDs for RMS (CLICK-MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-05-21","conditions":"Multiple Sclerosis","enrollment":100},{"nctId":"NCT04997148","phase":"","title":"Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-08-11","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":116},{"nctId":"NCT04121403","phase":"PHASE3","title":"Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS)","status":"COMPLETED","sponsor":"Oslo University Hospital","startDate":"2019-10-16","conditions":"Relapsing Multiple Sclerosis, Multiple Sclerosis","enrollment":267},{"nctId":"NCT04776213","phase":"PHASE4","title":"Cognition and HRQoL in Adults With Highly-active RMS in Year 3 and 4 After Initial Mavenclad® Dose (CLARIFY MS Extension)","status":"COMPLETED","sponsor":"Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany","startDate":"2021-02-23","conditions":"Multiple Sclerosis","enrollment":280},{"nctId":"NCT03745144","phase":"PHASE1","title":"Effects of Cladribine Tablets on the PK of Microgynon®","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2019-01-17","conditions":"Relapsing Multiple Sclerosis (RMS)","enrollment":28},{"nctId":"NCT05902429","phase":"PHASE4","title":"Effects of Oral Cladribine on Remyelination and Inflammation in Multiple Sclerosis Patients","status":"UNKNOWN","sponsor":"Pontificia Universidade Católica do Rio Grande do Sul","startDate":"2021-04-28","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":10},{"nctId":"NCT03961204","phase":"PHASE4","title":"Long-Term Outcomes and Durability of Effect Following Treatment With Cladribine Tablets for MS (CLASSIC-MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2019-08-15","conditions":"Multiple Sclerosis (MS)","enrollment":662},{"nctId":"NCT05330377","phase":"PHASE1","title":"GM-CLAG in Relapsed/Refractory FLT3-mutated AML","status":"WITHDRAWN","sponsor":"Ayman H Qasrawi","startDate":"2023-03","conditions":"Acute Myeloid Leukemia","enrollment":""},{"nctId":"NCT04640818","phase":"","title":"Safety and Efficacy of Cladribine Therapy After Anti CD20 Therapy","status":"UNKNOWN","sponsor":"Claudio Gobbi","startDate":"2020-12-17","conditions":"Multiple Sclerosis","enrollment":45},{"nctId":"NCT04550455","phase":"PHASE4","title":"A Prospective Biomarker Study in Active SPMS Subjects Treated With Cladribine Tablets","status":"UNKNOWN","sponsor":"Keith Edwards, M.D.","startDate":"2020-09-16","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT05019248","phase":"","title":"Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine","status":"UNKNOWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2020-09-01","conditions":"Multiple Sclerosis, Relapsing-Remitting, Vaccine Response Impaired","enrollment":260},{"nctId":"NCT00725985","phase":"PHASE3","title":"Oral Cladribine in Early Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-12-31","conditions":"Multiple Sclerosis","enrollment":617},{"nctId":"NCT00641537","phase":"PHASE3","title":"CLARITY Extension Study","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2008-02-29","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":867},{"nctId":"NCT00436826","phase":"PHASE2","title":"A Phase 2 Study of Cladribine Add-on to Interferon-beta (IFN-beta) Therapy in Multiple Sclerosis (MS) Subjects With Active Disease (ONWARD)","status":"COMPLETED","sponsor":"EMD Serono Research & Development Institute, Inc.","startDate":"2006-11-30","conditions":"Multiple Sclerosis","enrollment":172},{"nctId":"NCT00213135","phase":"PHASE3","title":"A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)","status":"COMPLETED","sponsor":"EMD Serono","startDate":"2005-04","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":1326}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":238,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Mavenclad"],"phase":"marketed","status":"active","brandName":"Cladribine Tablets","genericName":"Cladribine Tablets","companyName":"Keith Edwards, M.D.","companyId":"keith-edwards-m-d","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cladribine is a purine nucleoside analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing selective depletion of lymphocytes. Used for Hairy cell leukemia, Multiple sclerosis (relapsing forms).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}